Innate Pharma SA
IPHYF$211M
Micro CapNASDAQBiotechnology🇺🇸North America174 employees
Drugs in Pipeline
6
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
IPHYF News
Catalyst Timeline
0 upcoming, 0 past
No catalysts found.
Drug Pipeline
MIS416
Secondary Progressive Multiple Sclerosis
IPH4102
Lymphoma, T-Cell
IPH6501
Non Hodgkin Lymphoma
IPH2101
Smoldering Multiple Myeloma
Monalizumab
Head and Neck Neoplasms
IPH2102 at 0.1 mg/kg
Acute Myeloid Leukemia
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
MIS416 | Phase 2 | Secondary Progressive Multiple Sclerosis | - | - |
IPH4102 | Phase 2 | Lymphoma, T-Cell | - | - |
IPH6501 | Phase 2 | Non Hodgkin Lymphoma | - | - |
IPH2101 | Phase 2 | Smoldering Multiple Myeloma | - | - |
Monalizumab | Phase 2 | Head and Neck Neoplasms | - | - |
IPH2102 at 0.1 mg/kg | Phase 2 | Acute Myeloid Leukemia | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply